Investors Purchase Large Volume of Call Options on Bristol Myers Squibb (NYSE:BMY)

Bristol Myers Squibb Company (NYSE:BMY) saw unusually large options trading activity on Wednesday. Investors bought 66,895 call options on the stock. This represents an increase of 81% compared to the average daily volume of 37,032 call options.

Bristol Myers Squibb Stock Up 1.9%

Bristol Myers Squibb stock traded up $1.14 during trading hours on Wednesday, hitting $61.79. The company had a trading volume of 6,529,121 shares, compared to its average volume of 13,440,122. Bristol Myers Squibb has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The firm has a market capitalization of $126.15 billion, a P/E ratio of 17.94, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. The firm’s fifty day moving average is $59.03 and its 200-day moving average is $52.45.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. During the same quarter in the prior year, the firm earned $1.67 earnings per share. The company’s revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, research analysts forecast that Bristol Myers Squibb will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.1%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 73.04%.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Zacks highlights BMY’s strong earnings?surprise history and says the company currently shows the combinations that make another quarterly beat likely — this raises expectations for near?term upside when results are released. Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Late?stage Camzyos data: adolescent Phase 3 results met the primary endpoint with no new safety signals — a clear path to label expansion would increase addressable market for BMY’s cardiovascular franchise. Camzyos Adolescent Trial Success Might Change The Case For Investing In Bristol-Myers Squibb (BMY)
• Positive Sentiment: Institutional interest: Ariel Global Fund re?added BMY citing pipeline strength and attractive valuation — a sign of fundamental investor conviction that can support share price. Ariel Global Fund Re-Added Bristol-Myers Squibb Company (BMY) on Pipeline Strength and Attractive Valuation
• Neutral Sentiment: Market opportunity: Research reports project multi?billion dollar growth in advanced renal cell carcinoma and broader kidney cancer drug markets over 2026–2030 — positive for long?term TAM but not an immediate revenue driver. Advanced Renal Cell Carcinoma Treatment Market to Grow by $3.1 Billion During 2026-2030
• Neutral Sentiment: Kidney cancer drugs market growth report underscores expanding demand where BMY competes — supportive background for franchise growth but incremental and multi?year. Kidney Cancer Drugs Market to Grow by $2 Billion During 2026-2030
• Neutral Sentiment: Corporate/CSR update: BMY marks a decade of programs to advance care in multiple myeloma — positive PR but limited short?term stock impact. Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma
• Neutral Sentiment: Short?term trading note: market writeups show the stock has risen recently but still lags broader market performance — suggests momentum but possible relative weakness. Bristol Myers Squibb Co. stock rises Tuesday, still underperforms market
• Negative Sentiment: Analyst outlook mixed: coverage notes “mixed analyst sentiment” which can limit upside if analysts issue cautious revisions or downgrades after earnings or pipeline readouts. Bristol-Myers Squibb (BMY) faces mixed analyst sentiment despite strong momentum in healthcare industry

Institutional Investors Weigh In On Bristol Myers Squibb

Large investors have recently made changes to their positions in the company. J. Derek Lewis & Associates Inc. acquired a new stake in Bristol Myers Squibb in the 4th quarter worth approximately $432,000. Osbon Capital Management LLC acquired a new position in Bristol Myers Squibb during the fourth quarter valued at approximately $55,000. World Investment Advisors raised its position in shares of Bristol Myers Squibb by 14.1% in the fourth quarter. World Investment Advisors now owns 64,471 shares of the biopharmaceutical company’s stock valued at $3,478,000 after purchasing an additional 7,977 shares during the period. Nalls Sherbakoff Group LLC bought a new position in shares of Bristol Myers Squibb in the fourth quarter valued at approximately $92,000. Finally, Larry Mathis Financial Planning LLC acquired a new stake in shares of Bristol Myers Squibb in the fourth quarter worth $427,000. Institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on BMY shares. Citigroup boosted their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a report on Friday, February 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Monday, March 23rd. Leerink Partners increased their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a report on Tuesday, January 13th. Piper Sandler reaffirmed an “overweight” rating and issued a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, February 23rd. Finally, Royal Bank Of Canada started coverage on Bristol Myers Squibb in a report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price target on the stock. Nine analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $61.41.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late?stage pipeline reflect a strong emphasis on cancer and immune?mediated conditions.